AR092993A1 - Laquinimod para reducir el daño talamico en la esclerosis multiple - Google Patents

Laquinimod para reducir el daño talamico en la esclerosis multiple

Info

Publication number
AR092993A1
AR092993A1 ARP130103705A ARP130103705A AR092993A1 AR 092993 A1 AR092993 A1 AR 092993A1 AR P130103705 A ARP130103705 A AR P130103705A AR P130103705 A ARP130103705 A AR P130103705A AR 092993 A1 AR092993 A1 AR 092993A1
Authority
AR
Argentina
Prior art keywords
laquinimod
subject
multiple sclerosis
damage
affected
Prior art date
Application number
ARP130103705A
Other languages
English (en)
Inventor
Comi Giancarlo
Filippi Massimo
Assunta Rocca Maria
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR092993A1 publication Critical patent/AR092993A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Método para inhibir o reducir el daño talámico en un sujeto que comprende administrarle al sujeto una cantidad de laquinimod, en donde el sujeto es un paciente humano afectado por una forma de esclerosis múltiple o que presenta un síndrome clínicamente aislado al que se le ha determinado que tiene daño talámico en condiciones basales, un sujeto afectado por una enfermedad o trastorno diferente de una forma de esclerosis múltiple o un síndrome clínicamente aislado, o un sujeto que no está afectado por una forma de esclerosis múltiple ni presenta un síndrome clínicamente aislado, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Métodos para inhibir o reducir el tremor o espasticidad en un sujeto afectado por tremor o espasticidad, que comprende administrarle al sujeto una cantidad de laquinimod, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Reivindicación 51: Laquinimod caracterizado porque es para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales. Reivindicación 52: Una composición farmacéutica caracterizada porque comprende una cantidad de laquinimod para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales.
ARP130103705A 2012-10-12 2013-10-11 Laquinimod para reducir el daño talamico en la esclerosis multiple AR092993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
AR092993A1 true AR092993A1 (es) 2015-05-13

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103705A AR092993A1 (es) 2012-10-12 2013-10-11 Laquinimod para reducir el daño talamico en la esclerosis multiple

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2018053040A1 (en) * 2016-09-13 2018-03-22 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with chs-131
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276393A1 (en) * 2005-01-13 2006-12-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
CA2657716A1 (en) * 2006-07-17 2008-01-24 Novartis Ag Cholanic acid amides
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
JP5859438B2 (ja) * 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたbdnf関連疾患の治療
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
BR112013014061A2 (pt) * 2010-12-07 2016-09-13 Teva Pharma uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla
CA2830027C (en) * 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Also Published As

Publication number Publication date
IL237745A0 (en) 2015-05-31
US20160296511A1 (en) 2016-10-13
WO2014058979A8 (en) 2015-04-16
CL2015000732A1 (es) 2015-08-07
TW201420101A (zh) 2014-06-01
AU2017203896A1 (en) 2017-06-29
WO2014058979A3 (en) 2015-08-20
CN105263325A8 (zh) 2017-07-14
EA201590726A1 (ru) 2015-10-30
EP2961406A2 (en) 2016-01-06
BR112015007782A2 (pt) 2017-07-04
CN105263325A (zh) 2016-01-20
EP2961406A4 (en) 2017-01-04
AU2013329348A1 (en) 2015-05-28
MX2015004564A (es) 2015-07-21
KR20150080509A (ko) 2015-07-09
PE20151435A1 (es) 2015-10-15
US20140107154A1 (en) 2014-04-17
WO2014058979A2 (en) 2014-04-17
JP2015533163A (ja) 2015-11-19
SG11201501874TA (en) 2015-05-28
CL2016002873A1 (es) 2017-04-17
HK1218865A1 (zh) 2017-03-17
CA2884272A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
MX2015004565A (es) Metodo y dispositivo para conmutacion de camaras.
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2015533163A5 (es)
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
JP2013520447A5 (es)
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112016016098A2 (pt) Compostos orgânicos
BR112015012497A2 (pt) combinações farmacêuticas
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112013025368A8 (pt) Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
WO2013049280A3 (en) Sphingosine analogs, compositions, and methods related thereto

Legal Events

Date Code Title Description
FB Suspension of granting procedure